Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) and Cytosorbents (NASDAQ:CTSO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.
Institutional and Insider Ownership
33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Intelligent Bio Solutions and Cytosorbents”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $4.22 million | 1.35 | -$12.43 million | ($9.02) | -0.19 |
| Cytosorbents | $37.06 million | 0.40 | -$8.20 million | ($5.80) | -0.82 |
Cytosorbents has higher revenue and earnings than Intelligent Bio Solutions. Cytosorbents is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for Intelligent Bio Solutions and Cytosorbents, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 1 | 1 | 0 | 0 | 1.50 |
| Cytosorbents | 1 | 1 | 2 | 0 | 2.25 |
Cytosorbents has a consensus price target of $74.83, suggesting a potential upside of 1,470.81%. Given Cytosorbents’ stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than Intelligent Bio Solutions.
Profitability
This table compares Intelligent Bio Solutions and Cytosorbents’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -294.88% | -175.35% | -91.25% |
| Cytosorbents | -48.94% | -431.65% | -41.94% |
Volatility & Risk
Intelligent Bio Solutions has a beta of 4.48, indicating that its stock price is 348% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Summary
Cytosorbents beats Intelligent Bio Solutions on 9 of the 14 factors compared between the two stocks.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
